SyntheticMR Future Growth

Future criteria checks 5/6

SyntheticMR is forecast to grow earnings and revenue by 47.4% and 18.8% per annum respectively. EPS is expected to grow by 47.4% per annum. Return on equity is forecast to be 29.5% in 3 years.

Key information

47.4%

Earnings growth rate

47.4%

EPS growth rate

Healthcare Services earnings growth	29.7%
Revenue growth rate	18.8%
Future return on equity	29.5%
Analyst coverage	Low
Last updated	21 Feb 2024

Recent future growth updates

Recent updates

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Nov 29

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Aug 06

Why SyntheticMR AB (publ) (NGM:SYNT) Could Be Worth Watching

Feb 23

A Look At The Intrinsic Value Of SyntheticMR AB (publ) (NGM:SYNT)

Jan 27

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

Nov 10

Read This Before Selling SyntheticMR AB (publ) (NGM:SYNT) Shares

Mar 09

What Percentage Of SyntheticMR AB (publ) (NGM:SYNT) Shares Do Insiders Own?

Feb 11

SyntheticMR AB (publ) (NGM:SYNT) Insiders Increased Their Holdings

Dec 03

Earnings and Revenue Growth Forecasts

NGM:SYNT - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	181	55	47	N/A	1
12/31/2025	145	39	28	N/A	1
12/31/2024	112	23	8	N/A	1
12/31/2023	94	10	-17	-7	N/A
9/30/2023	85	6	-19	-9	N/A
6/30/2023	83	6	-26	-15	N/A
3/31/2023	80	7	-28	-17	N/A
12/31/2022	74	6	-26	-15	N/A
9/30/2022	71	8	-19	-9	N/A
6/30/2022	65	7	-12	-4	N/A
3/31/2022	58	2	-6	0	N/A
12/31/2021	63	8	-1	4	N/A
9/30/2021	60	8	-1	3	N/A
6/30/2021	57	5	-8	-3	N/A
3/31/2021	55	3	-9	-3	N/A
12/31/2020	52	1	-14	-9	N/A
9/30/2020	47	-6	-14	-9	N/A
6/30/2020	48	-3	-5	-1	N/A
3/31/2020	51	2	-2	3	N/A
12/31/2019	48	4	9	13	N/A
9/30/2019	53	12	11	14	N/A
6/30/2019	52	13	15	18	N/A
3/31/2019	50	14	18	21	N/A
12/31/2018	51	15	15	18	N/A
9/30/2018	49	14	16	19	N/A
6/30/2018	45	12	12	15	N/A
3/31/2018	39	8	11	14	N/A
12/31/2017	38	8	8	11	N/A
9/30/2017	34	8	N/A	11	N/A
6/30/2017	30	7	N/A	9	N/A
3/31/2017	28	6	N/A	6	N/A
12/31/2016	22	2	N/A	4	N/A
9/30/2016	15	1	N/A	0	N/A
6/30/2016	14	4	N/A	-1	N/A
3/31/2016	11	1	N/A	-3	N/A
12/31/2015	9	0	N/A	-5	N/A
9/30/2015	7	-4	N/A	-5	N/A
6/30/2015	5	-9	N/A	-6	N/A
3/31/2015	5	-8	N/A	-4	N/A
12/31/2014	4	-7	N/A	-3	N/A
9/30/2014	5	-6	N/A	-3	N/A
6/30/2014	5	-5	N/A	-3	N/A
3/31/2014	5	-5	N/A	-3	N/A
12/31/2013	4	-5	N/A	-4	N/A
9/30/2013	4	-4	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SYNT's forecast earnings growth (47.4% per year) is above the savings rate (0.9%).

Earnings vs Market: SYNT's earnings (47.4% per year) are forecast to grow faster than the Swedish market (13.4% per year).

High Growth Earnings: SYNT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SYNT's revenue (18.8% per year) is forecast to grow faster than the Swedish market (1.6% per year).

High Growth Revenue: SYNT's revenue (18.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SYNT's Return on Equity is forecast to be high in 3 years time (29.5%)

SyntheticMR Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 28%

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 17%

Consensus EPS estimates increase by 18%

Consensus EPS estimates fall by 14%

Recent updates

SyntheticMR AB Receives Regulatory Approval for SyMRI 15 in Australia

SyntheticMR AB (publ) to Report Q3, 2024 Results on Nov 19, 2024

SyntheticMR Announces Appointment of Francois Hebert as New President, North America

SyntheticMR Receives Regulatory Approval for Symri in Taiwan

SyntheticMR AB (publ) to Report Q2, 2024 Results on Aug 27, 2024

SyntheticMR AB (publ) Announces Board Changes

SyntheticMR AB (publ) to Report Q1, 2024 Results on May 21, 2024

SyntheticMR AB (publ), Annual General Meeting, May 21, 2024

SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D

SyntheticMR AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking

SyntheticMR Has Submitted Their Next Generation Solution, SyMRI 3D for 510(K) Clearance

SyntheticMR Appoints Nomination Committee for the 2024 Annual General Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

SyntheticMR AB (publ) to Report Nine Months, 2023 Results on Nov 10, 2023

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Now 22% undervalued after recent price drop

SyntheticMR AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Now 20% undervalued after recent price drop

SyntheticMR Releases A New Update to SyMRI 11.3.11 & 12.1.11

SyntheticMR Introduces Quantitative Neuro Reports to Enhance Clinical Workflow

SyntheticMR Receives Regulatory Approval for Their Innovative SyMRI Software Solution in South Korea

Consensus EPS estimates fall by 28%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Some Investors May Be Worried About SyntheticMR's (NGM:SYNT) Returns On Capital

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

Full year 2022 earnings released: EPS: kr0.15 (vs kr0.20 in FY 2021)

Now 24% undervalued after recent price drop

SyntheticMR AB (publ), Annual General Meeting, May 23, 2023

Consensus EPS estimates fall by 17%

Now 21% undervalued after recent price drop

SyntheticMR AB (publ) to Report Fiscal Year 2022 Results on Feb 15, 2023

Now 20% undervalued after recent price drop

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

No independent directors

Now 21% undervalued after recent price drop

SyntheticMR Receives EU Medical Device Regulation (Mdr) Certificate

SyntheticMR AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

SyntheticMR's SyMRI MSK Software for Knee and Spine Imaging Receives Regulatory Approval in Brazil

Consensus EPS estimates increase by 18%

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

Consensus EPS estimates fall by 14%

Consensus EPS estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

SyntheticMR AB (publ) to Report First Half, 2022 Results on Aug 23, 2022

SyntheticMR's Quantitative MRI Solution Symri Neuro Compatible with Philips Smartspeed to Support Shorter Scan Times

Dr. Jeff Miller Joins SyntheticMR's Medical Advisory Board

SyMRI MSK from SyntheticMR is Now Available on syngo.via Open Apps from Siemens Healthineers

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 19%

Price target decreased to kr36.00

No independent directors

Full year 2021 earnings: EPS misses analyst expectations

SyntheticMR AB (publ), Annual General Meeting, May 10, 2022

SyntheticMR AB (publ) to Report Q1, 2022 Results on May 10, 2022

Now 24% undervalued after recent price drop

Syntheticmr AB (Publ) Announces Net Sales Guidance for the First Quarter 2022

Now 21% undervalued after recent price drop

Full year 2021 earnings: EPS misses analyst expectations

Why SyntheticMR AB (publ) (NGM:SYNT) Could Be Worth Watching

Now 21% undervalued after recent price drop

A Look At The Intrinsic Value Of SyntheticMR AB (publ) (NGM:SYNT)